Copyright Reports & Markets. All rights reserved.

Global CXCR4 Antagonists Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 CXCR4 Antagonists Market Overview

    • 1.1 Product Overview and Scope of CXCR4 Antagonists
    • 1.2 Classification of CXCR4 Antagonists by Types
      • 1.2.1 Global CXCR4 Antagonists Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global CXCR4 Antagonists Revenue Market Share by Types in 2018
      • 1.2.3 BL-8040
      • 1.2.4 GMI-1359
      • 1.2.5 Plerixafor (AMD3100)
      • 1.2.6 Balixafortide (POL6326)
      • 1.2.7 USL311
      • 1.2.8 Others
    • 1.3 Global CXCR4 Antagonists Market by Application
      • 1.3.1 Global CXCR4 Antagonists Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Cancer
      • 1.3.3 HIV
      • 1.3.4 Chronic Inflammatory Diseases
    • 1.4 Global CXCR4 Antagonists Market by Regions
      • 1.4.1 Global CXCR4 Antagonists Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) CXCR4 Antagonists Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) CXCR4 Antagonists Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) CXCR4 Antagonists Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) CXCR4 Antagonists Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) CXCR4 Antagonists Status and Prospect (2014-2024)
    • 1.5 Global Market Size of CXCR4 Antagonists (2014-2024)

    2 Company Profiles

    • 2.1 Biokine Therapeutics
      • 2.1.1 Business Overview
      • 2.1.2 CXCR4 Antagonists Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Biokine Therapeutics CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 GlycoMimetics
      • 2.2.1 Business Overview
      • 2.2.2 CXCR4 Antagonists Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 GlycoMimetics CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Eli Lilly
      • 2.3.1 Business Overview
      • 2.3.2 CXCR4 Antagonists Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Eli Lilly CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 BioLineRx
      • 2.4.1 Business Overview
      • 2.4.2 CXCR4 Antagonists Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 BioLineRx CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Sanofi
      • 2.5.1 Business Overview
      • 2.5.2 CXCR4 Antagonists Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Sanofi CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 X4 Pharmaceuticals
      • 2.6.1 Business Overview
      • 2.6.2 CXCR4 Antagonists Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 X4 Pharmaceuticals CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Upsher-Smith Laboratories
      • 2.7.1 Business Overview
      • 2.7.2 CXCR4 Antagonists Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Upsher-Smith Laboratories CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Merck
      • 2.8.1 Business Overview
      • 2.8.2 CXCR4 Antagonists Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Merck CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Roche
      • 2.9.1 Business Overview
      • 2.9.2 CXCR4 Antagonists Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Roche CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Harmonic Pharma
      • 2.10.1 Business Overview
      • 2.10.2 CXCR4 Antagonists Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Harmonic Pharma CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2018)

    3 Global CXCR4 Antagonists Market Competition, by Players

    • 3.1 Global CXCR4 Antagonists Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 CXCR4 Antagonists Players Market Share
      • 3.2.2 Top 10 CXCR4 Antagonists Players Market Share
    • 3.3 Market Competition Trend

    4 Global CXCR4 Antagonists Market Size by Regions

    • 4.1 Global CXCR4 Antagonists Revenue and Market Share by Regions
    • 4.2 North America CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 4.3 Europe CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 4.5 South America CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa CXCR4 Antagonists Revenue and Growth Rate (2014-2019)

    5 North America CXCR4 Antagonists Revenue by Countries

    • 5.1 North America CXCR4 Antagonists Revenue by Countries (2014-2019)
    • 5.2 USA CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 5.3 Canada CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico CXCR4 Antagonists Revenue and Growth Rate (2014-2019)

    6 Europe CXCR4 Antagonists Revenue by Countries

    • 6.1 Europe CXCR4 Antagonists Revenue by Countries (2014-2019)
    • 6.2 Germany CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 6.3 UK CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 6.4 France CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 6.5 Russia CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 6.6 Italy CXCR4 Antagonists Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific CXCR4 Antagonists Revenue by Countries

    • 7.1 Asia-Pacific CXCR4 Antagonists Revenue by Countries (2014-2019)
    • 7.2 China CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 7.3 Japan CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 7.4 Korea CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 7.5 India CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia CXCR4 Antagonists Revenue and Growth Rate (2014-2019)

    8 South America CXCR4 Antagonists Revenue by Countries

    • 8.1 South America CXCR4 Antagonists Revenue by Countries (2014-2019)
    • 8.2 Brazil CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia CXCR4 Antagonists Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue CXCR4 Antagonists by Countries

    • 9.1 Middle East and Africa CXCR4 Antagonists Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 9.3 UAE CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria CXCR4 Antagonists Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa CXCR4 Antagonists Revenue and Growth Rate (2014-2019)

    10 Global CXCR4 Antagonists Market Segment by Type

    • 10.1 Global CXCR4 Antagonists Revenue and Market Share by Type (2014-2019)
    • 10.2 Global CXCR4 Antagonists Market Forecast by Type (2019-2024)
    • 10.3 BL-8040 Revenue Growth Rate (2014-2024)
    • 10.4 GMI-1359 Revenue Growth Rate (2014-2024)
    • 10.5 Plerixafor (AMD3100) Revenue Growth Rate (2014-2024)
    • 10.6 Balixafortide (POL6326) Revenue Growth Rate (2014-2024)
    • 10.7 USL311 Revenue Growth Rate (2014-2024)
    • 10.8 Others Revenue Growth Rate (2014-2024)

    11 Global CXCR4 Antagonists Market Segment by Application

    • 11.1 Global CXCR4 Antagonists Revenue Market Share by Application (2014-2019)
    • 11.2 CXCR4 Antagonists Market Forecast by Application (2019-2024)
    • 11.3 Cancer Revenue Growth (2014-2019)
    • 11.4 HIV Revenue Growth (2014-2019)
    • 11.5 Chronic Inflammatory Diseases Revenue Growth (2014-2019)

    12 Global CXCR4 Antagonists Market Size Forecast (2019-2024)

    • 12.1 Global CXCR4 Antagonists Market Size Forecast (2019-2024)
    • 12.2 Global CXCR4 Antagonists Market Forecast by Regions (2019-2024)
    • 12.3 North America CXCR4 Antagonists Revenue Market Forecast (2019-2024)
    • 12.4 Europe CXCR4 Antagonists Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific CXCR4 Antagonists Revenue Market Forecast (2019-2024)
    • 12.6 South America CXCR4 Antagonists Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa CXCR4 Antagonists Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Scope of the Report:
      The global CXCR4 Antagonists market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of CXCR4 Antagonists.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the CXCR4 Antagonists market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the CXCR4 Antagonists market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Biokine Therapeutics
      GlycoMimetics
      Eli Lilly
      BioLineRx
      Sanofi
      X4 Pharmaceuticals
      Upsher-Smith Laboratories
      Merck
      Roche
      Harmonic Pharma

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      BL-8040
      GMI-1359
      Plerixafor (AMD3100)
      Balixafortide (POL6326)
      USL311
      Others

      Market Segment by Applications, can be divided into
      Cancer
      HIV
      Chronic Inflammatory Diseases
      Buy now